FY2024 Financial Results

from the beginning

FY2024 Financial Results

Cautionary Statement Regarding Forward-Looking Information

I. FY2024 Consolidated Financial Results

• FY2024 Financial Results: Overview

• FY2024 Financial Results

• FY2024 Financial Results: Main Brands

• FY2024 Financial Results：SMT(Sustainable Margin Transformation)

• Drivers of Core OP Growth

II. FY2024 Pipeline Update

• Main Brands: FY2024 Key Events

• Progress in Focus Area Approach (1/2): ASP3082 (Targeted Protein Degradation)

• Progress in Focus Area Approach (2/2): AT845 (Genetic Regulation)

III. FY2025 Outlook

• End-to-End Activities Along Patient Axis

• FY2025 Outlook: Overview

• FY2025 Forecast: Main Brands

• PADCEV & VYLOY: Business Update and Outlook

• IZERVAY: Business Update and Outlook (US)

• Image of Profit Contribution from Strategic Brands

• Strategic Brands: FY2025 Key Expected Events

• Focus Area Approach: Future Outlook

• FY2025 Forecast

• Key Takeaways

Appendix

• Strategic Brands: Potential Peak Sales (as of Apr 2025)

• Capital Allocation

• FY2024 Actual: FX Rate

• FY2025 Forecast: FX Rate & FX Sensitivity

• Balance Sheet & Cash Flow Highlights

• Balance of Bonds and Borrowings Highlights

• Main Intangible Assets (as of Mar 31, 2025)

• Sustainable Margin Transformation

• Lifecycle Management of Strategic Brands

• Progress in Focus Area Approach:Current Status of Programs in Clinical Trial

• Overview of Primary Focus Flagship Programs (1/2)

• Overview of Primary Focus Flagship Programs (2/2)

• Robust Pipeline of Astellas

• Progress in Overall Pipeline

• Strategic Brands: Status Update

• enfortumab vedotin (EV)(1/7): Nectin-4 Targeted ADC Overview of Development

• enfortumab vedotin (EV)(2/7): Clinical Studies

• enfortumab vedotin (EV)(3/7): Study Data by Disease Stage of UC

• enfortumab vedotin (EV)(4/7): Study Data in 1L mUC (EV-302)

• enfortumab vedotin (EV)(5/7): Development for Muscle-invasive bladder cancer (MIBC)

• enfortumab vedotin (EV)(6/7): Development for Non-muscle-invasive bladder cancer (NMIBC)

• enfortumab vedotin (EV)(7/7): Study Data in Solid Tumors Other than Urothelial Cancer (EV-202)

• avacincaptad pegol (ACP):Complement C5 Inhibitor / Pegylated RNA Aptamer

• fezolinetant: NK3 receptor antagonist

• zolbetuximab: Anti-Claudin 18.2 Monoclonal Antibody

• gilteritinib: FLT3 Inhibitor

• enzalutamide (1/2): Androgen Receptor Inhibitor

• enzalutamide (2/2): Phase 3 Study Data by Disease Stage

On the forefront of healthcare changeto turn innovative scienceinto VALUE for patients

Q&A

• Q&A 1

• Q&A 2

• Q&A 3

• Q&A 4

• Q&A 5

• Q&A 6

• Q&A 7

• Q&A 8